Published in Hematology Week, November 10th, 2003
In a recent study from Italy, "The biological activity of MEN 11079, a new daunorubucin analogue with a fluorine atom in C-8 of ring A, was investigated in the human leukemic cell lines K-562 and in mononuclear cells (MNCs) of 40 patients with acute myeloid leukemia (AML) and the activity compared to two well-characterized anthracyclines, idarubicin (IDA) and doxorubicin (DOXO)."
"IDA and MEN 11079 were more active than DOXO in cytotoxicity tests (WST-1 assay)," reported M. Biscardi and coauthors at the University of Florence. "IDA and MEN 11079 ID50 values were also significantly...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hematology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.